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1. Background
Healthcare practice requires progress 
driven by evidence. Randomized clin-
ical trials (RCTs) are often considered 
the gold standard for gathering evi-
dence in medicine. Unfortunately, RCTs 
have their own limitations and some-
times even statistically-significant results 
lack clinical significance.1 Strict inclusion 
and exclusion criteria limit access to 
RCTs for patients with chronic diseases, 
comorbidities, the elderly, women and 
children.2 As a consequence, one can 
observe variations and disparities in 
care and a lack, inconclusiveness or 
poor quality of evidence for clinical 
practice.3 The Learning Healthcare 
System (LHS) is offered as an answer 
to these problems. The Institute of 
Medicine defines an LHS as a system in 
which “science, informatics, incentives, 
and culture are aligned for continuous 
improvement and innovation, with best 
practices seamlessly embedded in the 
delivery process and new knowledge 
captured as an integral by-product of 
the delivery experience.”4 As indicated 
by Charles P. Friedman, the essence of 
the LHS is an information loop in which 
data are assembled, analyzed, inter-
preted and then come back to a system 
in form of an innovative practice.5 
This section features original work on ethical, legal, policy, and social 
aspects of the use of computing and information technology in health, 
biomedical research, and the health professions. For submissions, con-
tact Kenneth Goodman at: kgoodman@med.miami.edu
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The LHS uses medical records and 
computing power to test hypotheses 
and find causative factors of health and 
disease. In their report, Thomas Foley 
and Fergus Fairmichael differentiate five 
areas where the idea of the LHS could 
be applied: (1) comparative effective-
ness studies, (2) so-called “positive 
deviants” analysis, (3) real-time surveil-
lance, (4) predictive models, and (5) clin-
ical decision support systems.6 In this 
paper, we will refer chiefly to the third 
kind of application of the LHS, namely, 
real-time surveillance, but our argument 
could be applied to all five areas.
The existing ethical and regulatory 
framework is not adjusted to the LHS. 
In many developed countries, research-
ers encounter problems with launching 
and carrying out research projects.7 
Some researchers and bioethicists share 
a belief that the existing regulations 
overprotect research subjects, and by 
doing so, deprive them of better health-
care.8 For instance, an ethics review 
can significantly impede multicenter 
research projects and generate immense 
costs.9 There are discrepancies in the 
procedures of ethical review and inter-
pretations of existing regulations.10 Also, 
obtaining informed consent in large-
scale projects is sometimes infeasible. 
In other cases, the pursuit of informed 
consent can skew the research sample, 
because even if a research project poses 
very low risk, significantly lower num-
bers of people respond to a call for par-
ticipation, and a recruited group does 
not result in a representative sample.11
The LHS is sometimes considered to 
be a disruptive factor in medicine. Some 
authors argue that the LHS and the 
development of medicine have changed 
the very nature of both medical practice 
and research involving human subjects, 
blurring the difference between treat-
ing patients and conducting research.12 
Therefore, goes the argument, there 
should not be a distinction between 
practice and research but rather, the 
new category of a learning activity (LA) 
needs to be adopted. This change in 
nature of science should be followed 
by regulations and ethical guidelines 
which, according to this view, should 
become more permissive to facilitate 
research projects.
It seems plausible to adjust existing 
regulations and ethical guidelines in a 
way that facilitates low-risk safety and 
quality studies. However, the LHS—
which is a part of a wider process of digi-
talization in medicine13—raises myriad 
ethical questions. For instance, should 
a patient give her informed consent 
for a particular kind of research, or she 
should only be given an opt-out option? 
Who can gather, retain and process the 
health data of patients: healthcare facil-
ities, doctors, insurers, or researchers? 
Should access to health data be limited 
(and if so, how)? What is, and should 
be, the role of the government in creat-
ing the LHS? Below, we address some 
of these questions and want to under-
line that we do not refer to any particu-
lar healthcare system, country, or legal 
system. Instead, we aim at formulating 
general principles and guidelines that 
could be applicable to all countries 
affirming human rights, the rule of law, 
and democracy.
In the following sections, we show 
that the LHS does not abolish the differ-
ence between treatment and research, 
but rather adopts a new category of an 
LA. Further we argue that some learn-
ing activities have similar characteris-
tics to public health surveillance (PHS). 
We propose that these LAs and PHS 
should be similarly regulated, and 
should not require previous ethical 
review and informed consent. Rather, 
it should be conducted by a publicly-
controlled and supervised agent in 
accordance with national legal regu-
lations in a transparent and socially-
accountable manner.
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2. LHS and Public Health Surveillance
2.1. Dissolving a Treatment- Research 
Distinction?
There are five characteristics usually 
ascribed to research to distinguish it from 
practice: (i) research is mainly designed 
to develop generalizable knowledge; (ii) 
research requires systematic investiga-
tion; (iii) research is thought to present 
less net benefit and pose more risk and 
burden than practice; (iv) in the research 
context a, subject is exposed to more 
risk and burden than in the clinical set-
ting; and finally, (v) in practice, a patient 
is treated in accordance with the personal 
care standard, meaning that a physi-
cian adjusts the dosage to the individ-
ual needs of a patient and can carefully 
monitor the effects of the treatment. 
In contrast, a researcher is strictly lim-
ited by a research protocol, as a dosage 
is fixed and often no adjunctive treat-
ment is permitted.14
Nancy Kass, et al.15 ague that prog-
ress in medicine, and especially the 
development of the LHS, have led us 
to a point where medical practice and 
biomedical research pose similar risks 
to patients. According to these authors, 
there is no longer a significant conceptual 
and moral difference between practice 
and research. Instead, the new category 
of a learning activity (LA) should be 
adopted. An LA dissolves the distinction 
between practice and research because 
it can, by definition, be curing, diagnos-
ing or preventing, and at the same time, 
be a part of systematic collection of sci-
entific evidence and a tool for testing 
scientific hypotheses.
According to Kass and her colleagues, 
these five characteristics can be ascribed 
to medical practice within the frame-
work of the LHS. Medical records from 
the healthcare computer system are col-
lected and analyzed in a systematic man-
ner to produce generalizable knowledge 
that is then promptly applied in practice. 
Research does not always present less 
net benefit, and more risk and burden, 
than practice. For instance, in pediatric 
anticancer trials research can be consid-
ered, at least in some instances,16 the best 
available treatment.17 Moreover, when 
it is the case that an existing treatment 
is unproven, but still standard care, it is 
possible that during therapy a patient is 
exposed to unnecessary risk and burden. 
Finally, as well, the standard of personal 
care is limited to the framework of exist-
ing healthcare systems, due to the fact 
that physicians are constrained in their 
professional judgment by reimburse-
ment policies and the patient’s ability to 
pay. Moreover, new research protocols 
allow adjustments for experimental inter-
vention, according to patient’s needs.
Given the above, we perhaps do not 
need two different ethical frameworks, 
but only one set of ethical guidelines 
that should be applied to research pro-
tocols and medical practice.18 However, 
it is our position that this proposal does 
not provide a satisfactory solution.
We argue that different activities 
require different procedural safeguards, 
although these procedural safeguards 
can be justified using the same set of ethi-
cal principles. For example, we may have 
one uniform ethical framework, such as 
the one proposed by Ruth Faden, et al.,19 
but this ethical framework could be 
translated into different procedural 
requirements in different circumstances. 
However, in order to adapt a set of ethical 
principles to certain circumstances we 
need a rich conceptual framework that 
will allow us to differentiate and discrim-
inate among varieties of activities. In this 
context, the difference between research 
and practice appears to be important.
Let us consider three different learning 
activities: an RCT, an observational study, 
and medical practice. All three can be 
considered LAs, but are significantly 
different. RCTs often carry more risk 
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than observational studies. A double-
blind, placebo-controlled clinical trial 
assessing a new agent for general anxi-
ety disorder, when a proven treatment 
exists, poses more net risk to a partici-
pant than would an observational 
research study. But even an observa-
tional study can involve additional 
diagnostic procedures, for instance a 
set of intrusive questionnaires, and 
multiple blood tests that can interfere 
with the routine therapy of a patient 
diagnosed with general anxiety. Partici-
pation in an observational research 
project requiring additional diagnos-
tic procedures may not be in the 
patient’s best interests, although a 
study’s activities might be arranged in 
a way that make them difficult to dis-
tinguish from a routine diagnostic 
process. In routine medical practice, a 
physician may discuss with a patient 
different options of pharmacotherapy, 
including pharmacotherapy coupled 
with psychotherapy, or even off-label 
pharmacotherapy. All these options 
could be associated with different risk 
levels, but in the process of shared deci-
sion making, a patient and a psychiatrist 
can arrive at the best possible option 
from the patient’s perspective.20
In all three cases, different ethical 
problems can arise and researchers and 
physicians may try to resolve them by 
referring to the same ethical framework. 
A researcher may want to avoid impos-
ing nonclinical risk and burdens, and 
would try to limit them to a necessary 
list.21 The same principle would be fol-
lowed by the physician. But it seems 
clear that because of the very nature of 
these activities, all three would require 
different procedural safeguards. In the 
first case, informed consent is required, 
and a full ethics review is needed to 
ensure that the study does not pose 
excessive risk to research subjects. In 
the case of an observational study, at 
least abbreviated review would be 
necessary, followed by obtaining the 
patient’s informed consent. In the case of 
routine practice, an ethics review may be 
unnecessary, and the process of informed 
consent has different goals. Therefore, 
although ethical problems concerning all 
activities can be addressed within one 
ethical framework for an LHS, we still 
need different procedural and regulatory 
approaches: one for research, and one 
for medical practice. Moreover, the claim 
that the very nature of these activities 
is the same—namely, learning—may 
impede properly differentiating them 
and adjusting corresponding procedural 
safeguards.
An argument could be made that off-
label use is a special case that does not 
fall into either the research or practice 
category. If there is no evidence that an 
off-label drug is efficient and safe, then 
it does not meet one of the defining fea-
tures of practice, in that it does not 
guarantee a reasonable expectation of 
success.22 In that instance, a broader 
category of learning activity would be 
useful. But this argument seems to miss 
the point. First, not all medical activities 
have to be either research, or practice. 
Second, off-label use is not always with-
out evidence. It seems that off-label use 
might fall into at least three categories: 
supported by evidence, supposedly safe 
as well as effective, and investigational.23 
Only a suppositional off-label drug use, 
when only weak evidence of safety and 
efficacy exists, could pose a problem. 
Moreover, a new category of LA is not 
especially helpful in this case. We have 
only to decide what kind of standards 
should be applied to this type of off-
label use: those of practice, or those of 
research, or perhaps a third category 
with specially-adjusted regulations. By 
discriminating between different research 
activities, we can allow, for instance, a 
waiver of informed consent requirement 
or abbreviation of ethics review. This 
differentiation is done case-by-case, 
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because even if two studies fall into the 
same category, for example, pragmatic 
clinical trial, they can pose different risk 
and benefit ratios to their participants.24
The category of LA does not dissolve 
the practice-research distinction, because 
it does not resolve inherent tensions 
within a research setting. A researcher 
can sometimes face a conflict between 
the best interests of her patient and a 
willingness to develop new therapies.25 
This kind of conflict arises from the 
divergent goals of treating and con-
ducting research. There is a relation 
between a risk for a participant and 
the moral significance of the tensions 
between divergent goals of treating and 
research. As a result, special safeguards 
are needed to manage this tension when 
it increases. Within the LHS, a new cat-
egory of low-risk observational studies 
is possible. This is brought by techno-
logical advances—the ability to collect 
and analyze large amounts of data. This 
technological transformation does not 
imply a major change in methodology 
of RCTs or other studies. LHS research 
studies are in fact observational research 
studies, and that makes them similar to 
epidemiological and public health stud-
ies. LHS makes observational studies 
easier due to the application of comput-
ers and appropriate software. If one con-
siders an example of safety and quality 
improvement studies within the LHS, it 
becomes clear that they have the same 
characteristics and similar risk-benefit 
ratio as public health surveillance. 
Therefore, in our view, this is not the dis-
tinction between practice and research 
that is dissolved within LHS, but rather a 
distinction between some LAs and public 
health surveillance (PHS) activities.
2.2. Public Health Practice, Research and 
Learning Healthcare
The term “public health” can be under-
stood in several ways. However, it 
seems that when we limit the meaning 
of “public health” to the narrow defi-
nition proposed by Mark A. Rothstein, 
the transformation of healthcare sys-
tems into learning healthcare systems 
could be understood analogically to be 
public health interventions.26 According 
to Rothstein, public health intervention 
involves public officials with specific 
legal authority that balances private and 
public interests, aims to protect public 
health, and sometimes uses coercive 
measures. Marcel Verweij and Angus 
Dawson modify the definition of public 
health and propose that a public health 
intervention can be undertaken by non-
governmental bodies, but that it has to 
be an action involving the entire pop-
ulation that though engaging individ-
uals, is not necessarily beneficial for 
everyone.27 In that sense, the LHS 
becomes a part of the public health sur-
veillance system: within the LHS, data are 
collected and analyzed to protect pub-
lic health or enable early intervention. 
Lawrence O. Gostin and Lesley Stone 
seek to delineate public health law and 
claim that public health law embraces 
five elements: government, population, 
service, power to enforce certain behav-
ior, and limitation of this power.28 The 
power of the government can be used 
to directly regulate the behavior of per-
sons and professionals. Taking these 
characteristics into account, we can 
attempt to build a definition of public 
health intervention, as: an activity man-
dated by law or a government agency 
embedded in the legal system, that aims 
to protect and promote public health 
and prevent disease. This activity might 
be mandatory, and is not always in the 
best interests of an individual.
Public health surveillance (PHS) is 
defined as “the systematic, ongoing 
collection, management, analysis, and 
interpretation of data followed by the 
dissemination of these data to public 
health programs to stimulate public 
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health action.”29 Because of its system-
atic character that leads to generaliza-
tion, there is an ongoing debate as 
to whether PHS should be understood 
as research or as practice.30 As Amy 
Fairchild concludes, public health surveil-
lance is “simultaneously both research 
and practice.”31 That fits the definition 
of an LA. Moreover, the definition of 
PHS given by Stephen B. Thacker and 
Ruth Berkelman is similar to the core 
characteristic of the LHS, namely, a 
bidirectional feedback loop, as surveil-
lance comprises not only gathering data, 
but also implantation of certain polices. 
Therefore, it seems that rather than 
focusing on the blurred line between 
research and practice, we should be 
paying attention to similarities between 
the LHS and PHS. From this essential 
and descriptive recognition, we can draw 
a normative conclusion: to the extent 
that the LHS is similar to PHS, it should 
be governed by similar ethical principles, 
and similarly regulated.
3. How to Regulate Learning Activities?
3.1. Public Health and Research
Research ethics and research regulations 
significantly differ from public health 
ethics and public health laws. The main 
goal of research ethics is to protect indi-
vidual interests, weighing them against 
social benefit. Public health has an 
opposite goal: to protect the community 
and weigh public good against indi-
vidual freedoms.32 Research requires 
informed consent and ethics review. 
Public health activities are mandatory 
and are usually launched without prior 
ethics review. It seems puzzling that the 
two sometimes very similar activities 
are regulated and guided by such dif-
ferent ethical principles and legal rules.
Research was strictly regulated 
because it was rightly thought that a 
substantial number of research projects 
pose risks to participants and deprive 
them of the benefits of personalized care. 
Moreover, it was recognized that the 
development of medicine is only one 
of many different goods and there is 
no moral obligation to participate in 
medical research.33 The requirements of 
informed consent and an ethics review 
are then justified by the characteristics 
of some research projects. Public health 
practice is regulated in a different way, 
because the risks and benefits for the 
society and individuals are differently 
distributed in the context of the health 
protection and promotion, as well as 
disease prevention. Systematic gather-
ing of health data is necessary to detect 
health risk factors and prevent disease 
from spreading. Protection of the com-
mon good is a governmental responsi-
bility, and participation in public health 
activities could be considered a moral 
obligation. Evading participation either 
poses a risk or undermines a protection 
system, and in both cases, endangers 
the common good. Moreover, PHS does 
not pose significant risks to the subjects, 
and is conducted by state institutions 
that execute their duties as imposed by 
legislation. Therefore, PHS has not only 
legal but also moral aspects. A state’s 
legal actions are not just expressions of 
arbitrary will, but are an embodiment of 
the common will and political agreement 
between the citizens (in the case of a 
democratic state that respects human 
rights and rule of law) and as such, they 
have moral significance.
3.2. The Learning Healthcare System and 
Public Health Surveillance
Some activities in the LHS have the 
same characteristics as PHS. The list 
of such activates consists of databases 
tracking the safety of new drugs, safety-
monitoring of innovative medical prac-
tices, databases of clinical research, and 
comparative effectiveness studies using 
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medical records. The goal of these activ-
ities is exactly the same as PHS: to pro-
tect public health and prevent harm. 
Additionally, in the case of PHS, the risks 
for the patients are almost negligible, 
and primarily consist of infringement 
of privacy. The fact that all these activities 
are conducted by state agencies, or in 
close cooperation with state agencies, 
also provides these activities with pub-
lic legitimization.
3.3. What Makes Public Health Surveillance 
and the Learning Healthcare System 
Ethical?
The main and persistent problem of 
public health ethics is that we do not 
know where to draw a line between 
individual freedom and public good. 
This basic dilemma can be described in 
different ethical terms, but we have not, 
as yet, arrived at a commonly accepted 
solution.34 In liberal democracies, pub-
lic opinion requires moral justification 
of any limitation of personal freedom.35 
We propose that a LA which meets three 
conditions should not be the subject of 
an ethics review and should not require 
informed consent. These conditions are 
the following:
A. A comprehensive healthcare system 
condition. Research has to target the 
whole healthcare system (its safety, effi-
cacy, efficiency, or all patients suffer-
ing a certain condition). Public health 
is a common good, and the protection 
of public health may require reasonable 
limitations of individual liberty. Research 
using medical records to determine the 
safety, efficacy, or prevalence of a cer-
tain condition falls into the category 
of reasonable limitation of individual 
liberty. An individual is not exposed 
to any additional harm. The possibility 
of infringement of privacy in a properly-
working system seems less than in 
the case of standard healthcare and 
administrative procedures. It is also 
hard to imagine that research involv-
ing consented-to treatment, its efficacy, 
safety, and efficiency, could be wrong-
ful to a participant. The condition of 
comprehensiveness also implies that 
research does not discriminate, or target 
any specific population or community.
B. Research that is publicly transparent 
and open to public scrutiny. In the LHS, 
two levels of transparency are possible: 
(1) patients’ representatives can be 
directly involved in oversight of all 
research conducted in a healthcare sys-
tem. This information about research 
can be open to public scrutiny; and (2) 
the LHS can enable individual patients 
to see and control the research studies 
in which they are involved. Within the 
LHS, it is possible to create patients’ 
interfaces.36 A patient can thus have 
access to her electronic health record 
(EHR), follow which projects her data 
was used in, and find sufficient infor-
mation about these research projects.
C. Conducted by state health system or 
institution in collaboration with state. 
State and governmental institutions 
have public accountability, as well as 
strictly-defined goals and procedures. 
They therefore have legal and moral 
legitimacy to act. Also, to the extent 
that the goals of these institutions are in 
accordance with common interests, there 
is low risk of conflict of interests. Of 
course, there still is a risk of corruption 
or exceeding the legal authority.
We can briefly mention some exam-
ples of research that fall out of the scope 
of what is clearly ethically justified in 
the LHS. Research targeting a specific pop-
ulation. Some research targeting health 
problems of only one specific popula-
tion or group should be subject to an 
ethics review. This kind of research is 
not unethical in principle, but may 
require additional ethical safeguards: 
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an ethics review and informed consent. 
Research within the LHS that does not 
meet the condition of comprehensiveness 
can also pose a risk of group stigmati-
zation and discrimination. By the same 
token, research conducted by an external 
sponsor, though not in principle uneth-
ical, requires at least an ethics review. 
The ethics review and IRB/REC (Institu-
tional Research Board/Research Ethics 
Committee) body is built into the dem-
ocratic system, and plays an important 
role of public control over the research 
enterprise.37
Conclusion
It has become clear that the transforma-
tion of healthcare into a learning system 
does not dissolve an ethically-significant 
distinction between research and prac-
tice. Moreover, one ethical framework for 
all LAs does not exclude different regula-
tory requirements for different types of 
research. Therefore, as argued, RCTs, 
which pose more risk to participants 
should be subject to an ethics review 
in which participants have given their 
informed consent, whereas other kinds 
of study do not necessarily require such 
strict regulations. We demonstrated that 
some LAs in fact blur the difference 
between research and public health, and 
therefore should be regulated in a similar 
way. Finally, we formulated three condi-
tions of ethically-justified learning activi-
ties in health: a comprehensive healthcare 
condition, a public transparency con-
dition, and the requirement of collabo-
ration with a state health agency.
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